Table 4.
Comparison of participant characteristics by histological subtype among 476 neuroendocrine prostate cancer from Surveillance, Epidemiology, and End Results (SEER) 18 registries, 2004–2017.
| Characteristics | Total NEPC (n=476) | Pure NEPC (n=355) | NE differentiation (n=121) |
|---|---|---|---|
| N (%) orMean (SE)a | N (%) orMean (SE)a | N (%) orMean (SE)a | |
| Age at diagnosis, mean, years | 68.28 (0.47) | 68.31 (0.56) | 68.20 (0.88) |
| Age at diagnosis, years | |||
| <65 | 167 (35.08) | 125 (35.21) | 42 (34.71) |
| ≥65 | 309 (64.92) | 230 (64.79) | 79 (65.29) |
| Year of diagnosis | |||
| 2004–2010 | 185 (38.87) | 145 (40.85) | 40 (33.06) |
| 2011–2017 | 291 (61.13) | 210 (59.15) | 81 (66.94) |
| Race | |||
| White | 401 (84.24) | 297 (83.66) | 104 (85.95) |
| Black | 46 (9.66) | 35 (9.86) | 11 (9.09) |
| Others | 29 (6.09) | 23 (6.48) | 6 (4.96) |
| Tumor TNM stage | |||
| Stage II | 52 (10.92) | 40 (11.27) | 12 (9.92) |
| Stage III | 16 (3.36) | 10 (2.82) | 6 (4.96) |
| Stage IV | 390 (81.93) | 289 (81.41) | 101 (83.47) |
| Unknown | 18 (3.78) | 16 (4.51) | 2 (1.65) |
| Surgery, yes | 131 (27.52) | 93 (26.20) | 38 (31.40) |
| PSA level | |||
| ≤ 2.5 ng/ml | 116 (24.37) | 106 (29.86) | 10 (8.26) |
| 2.6–4.0 ng/ml | 41 (8.61) | 33 (9.30) | 8 (6.61) |
| 4.1–10.0 ng/ml | 109 (22.90) | 80 (22.54) | 29 (23.97) |
| 10.1–20.0 ng/ml | 51 (10.71) | 40 (11.27) | 11 (9.09) |
| > 20.0 ng/ml | 159 (33.40) | 96 (27.04) | 63 (52.07) |
| Survival time, mean, months | 20.04 (1.22) | 17.73 (1.34) | 26.81 (2.68) |
PSA, prostatic specific antigen; SE, Standard error; SEER, Surveillance, Epidemiology, and End Results.
aPresented as N and % (column percentage) or Mean and SE (standard error).